Rubedo Life Sciences

Health Care · Biotechnology
Lately:9 news stories in 90 daysFollow changes →

Facts

as of Nov 17, 2026

Rubedo Life Sciences is the Premier Longevity Company. Rubedo discovers and develops medicines to keep you biologically young.

Employees
51-200estimated range
Website
rubedolife.com

These are the key facts about Rubedo Life Sciences on Alion as of Nov 17, 2026. The latest round is Venture - Series Unknown of $40M, announced in 2024.

Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake

What the registers and the postings say about this employer.

Sanctions lists
OFAC SDN, EU consolidated
No match
Phishing reports
OpenPhish, Phishing.Database
None
Layoff notices
US WARN notices on file
None
Full employer checkScam signs in adverts, mail records, visa registers, domain history
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices

Financials

Funding rounds, investors and revenue on record.

$40MTotal raised
Venture - Series UnknownLatest round
1Rounds and grants
Money by yearUSD, rounds and grants
2024$40M1 record
Largest rounds and grants
Sources: funding announcements, grant and company registers

Milestones

Apr 22, 2024
Aug 2018
Each milestone is dated by its source: registers, filings, the press

Newsroom

top 7%Web presenceof 133.2M domains by links, Common Crawl
Sep 172026
News · news.qq.com
雄激素性脱发AGA临床试验将于2026年秋季启动由David Pariser医学博士美国医师学会会士、美国皮肤病学会会士牵头David Pariser曾任美国皮肤病学会会长并担任过450余项皮肤病临床试验的主要研究者 Rubedo旗下RLS-1496是目前首个且唯一进入临床试验的GPX4调节剂在人体离体雄激素性脱发AGA模型中展现...
Sep 172026
News · YahooFinance
MOUNTAIN VIEW, California, September 16, 2026--Rubedo Life Sciences, Inc. (Rubedo) anunció hoy un nuevo estudio clínico de RLS-1496, un tratamiento en investigación para paciente…
Sep 172026
News · Yahoo News
加州山景城, September 16, 2026--(美國商業資訊)--Rubedo Life Sciences, Inc. (Rubedo)今日宣布將於2026年10月啟動一項針對雄性遺傳性脫髮(AGA)病患的試驗中藥物RLS-1496的新臨床研究初步資料可望於2027年上半年公布該研究代表GPX4調節劑在脫髮治療中的首次臨床評估進一步擴大了RLS-…
Sep 162026
News · Estado de Minas
Ensaio clínico para alopecia androgenética (AGA) terá início no outono de 2026, liderado pelo Dr. David Pariser (MD, FACP, FAAD), ex-presidente da Academia Americana de Dermatolo…
Sources: the outlets named on each headline, each story once